CinCor Pharma, Inc., (CINC): Price and Financial Metrics

CinCor Pharma, Inc., (CINC): $29.06

0.14 (-0.48%)

POWR Rating

Component Grades








Add CINC to Watchlist
Sign Up

Industry: Biotech




#111 of 403

in industry

CINC Price/Volume Stats

Current price $29.06 52-week high $43.15
Prev. close $29.20 52-week low $10.53
Day low $29.02 Volume 6,349,700
Day high $29.35 Avg. volume 818,447
50-day MA $22.81 Dividend yield N/A
200-day MA $24.66 Market Cap 1.27B

CINC Stock Price Chart Interactive Chart >

CinCor Pharma, Inc., (CINC) Company Bio

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

CINC Latest News Stream

Event/Time News Detail
Loading, please wait...

CINC Latest Social Stream

Loading social stream, please wait...

View Full CINC Social Stream

Latest CINC News From Around the Web

Below are the latest news stories about CINCOR PHARMA INC that investors may wish to consider to help them evaluate CINC as an investment opportunity.

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor. On February 17, 2023, the Company received the official meeting minutes from the End-of-Phase 2 meeting with the FDA held on

Yahoo | February 21, 2023

CinCor CEO: acquisition by AstraZeneca was more than a year in the making

Before CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant.

Yahoo | January 26, 2023

Why These Two Biotech Stocks Blasted Higher This Week

Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence.

Yahoo | January 13, 2023

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.

Yahoo | January 11, 2023

AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout

AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.

Yahoo | January 10, 2023

Read More 'CINC' Stories Here

CINC Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2023 0.00%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!